[Etretinate therapy in solitary keratoacanthomas]

Area of Science:

• Dermatology
• Oncology

Context:

• Keratoacanthoma is a common skin tumor.
• Solitary centrofacial keratoacanthoma presents a clinical challenge.

Purpose:

• To evaluate the efficacy of etretinate in treating solitary centrofacial keratoacanthoma.

Summary:

• An open clinical trial treated 5 patients with solitary centrofacial keratoacanthoma using etretinate at 1.5 mg/kg.
• Complete healing was observed in all patients within 4-5 weeks.
• No recurrences were noted within a 3-month follow-up period.

Impact:

• Etretinate demonstrates significant therapeutic potential for solitary centrofacial keratoacanthoma.
• This treatment offers a promising option for managing this skin condition.